指南与共识姑息放疗与转移瘤放疗物理与技术

寡转移性癌症的临床管理:多学科肿瘤委员会建议在实践中的执行情况

Clinical management of oligometastatic cancer: Applying multidisciplinary tumor board recommendations in practice.
指南 / 共识 · Clin Transl Radiat Oncol · 2024-08-10

本研究在单一综合癌症中心筛查2020年全部肿瘤PET扫描,纳入影像学显示实体瘤寡转移、经多学科肿瘤委员会(MDT)讨论并在同中心治疗随访的患者,评估MDT建议的依从性与实施情况。结果显示MDT建议总体依从率83.7%,重大偏离与远处转移数目>1相关,且重大偏离与总生存显著更差相关。

要点

  • 787例影像学寡转移病例中,347例(44.1%)经MDT讨论,331例(42.1%)接受治疗并随访。
  • MDT最常推荐的治疗为全身治疗(35.6%)、含根治性局部治疗的多模式治疗(17.8%)和放疗(13.9%)。
  • 重大偏离发生率为16.3%,与远处转移数目>1相关(OR 1.85;95%CI 1.0-3.52),并与总生存显著更差相关(p=0.0034)。

核心结论

  • 寡转移性疾病患者对MDT建议的依从与实施总体较高(83.7%)。
  • 作者认为,通过更仔细和详尽地讨论寡转移患者特征与患者偏好,可能进一步减少重大偏离。

研究设计与样本

  • 单中心研究,筛查2020年全部肿瘤PET扫描,纳入影像学显示实体器官恶性肿瘤寡转移、经MDT讨论并在同中心治疗随访的患者。
  • 通过病历回顾获取临床数据,使用R软件进行统计计算。
  • 共识别787例寡转移病例,其中347例(44.1%)经MDT讨论,331例(42.1%)接受治疗并随访。

主要发现

  • MDT最常推荐的治疗为全身治疗(35.6%)、含根治性局部治疗的多模式治疗(17.8%)和放疗(13.9%)。
  • 重大偏离见于16.3%的病例,最常见原因为未执行任何MDT推荐治疗(19例,35.2%)、未执行全部MDT计划治疗(12例,22.2%)和执行额外治疗(11例,20.3%)。
  • 轻微偏离见于1.5%的病例。
  • 多因素回归显示,远处转移数目>1与重大偏离相关(OR 1.85;95%CI 1.0-3.52)。
  • 重大偏离与显著更差的总生存相关(p=0.0034)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Multidisciplinary tumor boards (MDTs) are an integral part of ensuring high-quality, evidence-based and personalized cancer care. In this study, we aimed to evaluate the adherence to and implementation of MDT recommendations in patients with oligometastatic disease (OMD). METHODS: We screened all oncologic positron emission tomography (PET) scans conducted at a single comprehensive cancer center in 2020. Patients were included if they had evidence of imaging-based OMD from a solid organ malignancy on the index scans, had their OMD case discussed at an MDT, and were treated and followed up at the same center. A switch away from the MDT-recommended treatment modalities was classified as a major deviation; non-MDT-mandated adjustments to a recommended treatment modality were coded as minor deviation. Clinical data was obtained via chart review; statistical calculations were computed using the R software. RESULTS: After review of PET and/or concurrent brain scans, 787 cases of OMD were identified. Thereof, 347 (44.1 %) cases were discussed at MDT, of which 331 (42.1 %) were therapeutically managed and subsequently followed. The three most commonly recommended therapies were systemic therapy (35.6 %), multimodality treatment including definitive local therapy (17.8 %), and radiotherapy (13.9 %). A major deviation was recorded in 16.3 % of cases (most commonly: none of the MDT-recommended treatment modalities were performed: 19 (35.2 %); not all MDT-planned treatment modalities were performed: 12 (22.2 %); and additional treatment modality was performed: 11 (20.3 %). A minor deviation was found in 1.5 % of cases. On multivariable regression, number of distant metastases (n > 1) was associated with a major deviation (OR: 1.85; 95 % CI, 1.0-3.52). Major deviations were associated with a significantly worse OS (p = 0.0034). CONCLUSIONS: Adherence to and implementation of MDT recommendations in OMD patients was generally high (83.7%). Major deviations might be further reduced by more careful and elaborate discussions of OMD patient characteristics s and patient preferences.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Christ SM, Breitenstein M, Heesen P, et al. Clinical management of oligometastatic cancer: Applying multidisciplinary tumor board recommendations in practice. Clin Transl Radiat Oncol. 2024. PMID: 39224662. doi:10.1016/j.ctro.2024.100838

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。